Cingulate Inc. (NASDAQ:CINGW) Short Interest Update
by Jessica Moore · The Cerbat GemCingulate Inc. (NASDAQ:CINGW – Get Free Report) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totaling 2,214 shares, a drop of 76.4% from the March 15th total of 9,399 shares. Based on an average daily trading volume, of 25,126 shares, the short-interest ratio is presently 0.1 days.
Cingulate Price Performance
NASDAQ:CINGW remained flat at $0.03 during trading hours on Friday. The company’s stock had a trading volume of 11,900 shares, compared to its average volume of 46,608. The company’s 50 day moving average is $0.05 and its 200 day moving average is $0.05. Cingulate has a 52 week low of $0.02 and a 52 week high of $0.18.
Cingulate Company Profile
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.